TOKYO—Global private equity firm Carlyle said on Wednesday it led a $312 million funding round for Japanese biotech company Spiber Inc, joining other global investors in betting on a growing number of late-stage Japanese startup firms.
Carlyle’s 10 billion yen ($91 million) stake in Spiber represents the group’s first non-buyout, minority investment in an unlisted startup in Japan, where startup funding is soaring.
